Stocklytics Platform
Asset logo for symbol MRUS
Merus NV
MRUS57
$55.29arrow_drop_up0.87%$0.48
Asset logo for symbol MRUS
MRUS57

$55.29

arrow_drop_up0.87%

Performance History

Chart placeholder
Key Stats
Open$56.54
Prev. Close$56.55
EPS-2.73
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range53.94
57.51
52 Week Range19.80
61.61
Ratios
EPS-2.73

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$857.46
Perf. (24h)
arrow_drop_up1.00%$8.56
Market Cap$764.35B
Price$565.33
Perf. (24h)
arrow_drop_up0.17%$0.98
Market Cap$519.41B
Price$154.69
Perf. (24h)
arrow_drop_down0.46%-$0.73
Market Cap$374.04B
Price$125.77
Perf. (24h)
arrow_drop_up1.22%$1.52
Market Cap$314.70B

About Merus NV (MRUS)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sven Ante Lundberg M.D.
Headquarters
Utrecht
Employees
164
Exchange
NASDAQ
add Merus NV to watchlist

Keep an eye on Merus NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Merus NV's (MRUS) price per share?

The current price per share for Merus NV (MRUS) is $55.29. The stock has seen a price change of $0.48 recently, indicating a 0.88% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Merus NV (MRUS)?

For Merus NV (MRUS), the 52-week high is $61.61, which is 11.43% from the current price. The 52-week low is $19.8, the current price is 179.17% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Merus NV (MRUS) a growth stock?

Merus NV (MRUS) has shown an average price growth of 0.41% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Merus NV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Merus NV (MRUS) stock price performance year to date (YTD)?

As of the latest data, Merus NV (MRUS) has a year-to-date price change of 93.19%. Over the past month, the stock has experienced a price change of 2.5%. Over the last three months, the change has been 38.88%. Over the past six months, the figure is 58.02%. Looking at a longer horizon, the five-year price change stands at 268.6%.

help
Is Merus NV (MRUS) a profitable company?

Merus NV (MRUS) has a net income of -$154.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -593.34% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $43.95M, with a revenue growth rate of 5.68%, providing insight into the company's sales performance and growth. Operating income is noted at -$156.55M. Furthermore, the EBITDA is -$164.04M.

help
What is the market capitalization of Merus NV (MRUS)?

Merus NV (MRUS) has a market capitalization of $3.69B. The average daily trading volume is 871.96K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level